-
Posted by
Two Blokes Apr 28 -
Filed in
Stock
-
2 views
ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the UK liquid biopsy specialist, has unveiled new data showing its experimental HER2-CTC blood test delivers high sensitivity and specificity, bolstering its development programme for the cancer assay. The results, to be presented at the American Association for Cancer Research meeting in Chicago, confirm that the test can detect HER2-positive circulating tumour cells (CTCs) from a simple blood sample with over 98% accuracy.
